Zimmer Biomet (ZBH) Q2 Revenue Jumps 7%
Zimmer Biomet (NYSE:ZBH), an orthopedic medical technology company, reported its earnings on August 7, 2025. The company announced GAAP revenue of $2.077 billion, beating analyst estimates of $2.057 billion. Adjusted earnings per share (EPS), a profitability metric that excludes certain non-recurring items, came in at $2.07, which was ahead of the consensus of $1.98 non-GAAP EPS. These results reflect a year-over-year revenue growth of 7.0% on a reported (GAAP) basis and a 3.0% increase in adjusted EPS. The quarter demonstrated progress in new product launches and strength in several core business units, though some margin pressure and segment challenges remain.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Zimmer Biomet operates in the global medical technology sector, specializing in orthopedic devices, implants, and related technologies. The company provides products such as joint replacements, surgical tools, and robotic-assisted surgical systems. Its offerings help improve mobility and quality of life for patients undergoing procedures like hip and knee replacements.
Source Fool.com
